The FDA advisory panel has narrowly voted to relax bans on four specific compounded peptides, a decision that could significantly impact the market for these substances.
This decision comes amidst ongoing debates about the safety of these peptides, with some advisers having ties to the industry, raising questions about the impartiality of the vote.
The easing of restrictions may lead to increased availability of these peptides, but it also highlights the need for careful monitoring of their safety and efficacy.